Clinical trial NCT00370890: A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Official title: A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Nasopharyngeal Cancer
Keywords: nasopharyngeal cancer
adjuvant chemotherapy
EBV DNA
PET CT scan
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Hong Kong Nasopharyngeal Cancer Study Group Limited
First posted: 2006-09-01
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to study the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in high risk NPC patients with residual EBV DNA following primary radiotherapy with or without concurrent cisplatin.

Detailed description: * The standard treatment for nasopharynx cancer is a course of radiotherapy with or without concurrent chemotherapy. This will cure about 80% of patients. For the 20% who developed recurrence or metastases, the prognosis is poor.
* Elevated EBV-DNA in plasma at end of radiotherapy has been shown to predict disease recurrence and may be a marker of subclinical residual disease.
* This study aims to test whether adjuvant treatment with 6 cycles of a modern chemotherapy regimen (gemcitabine and cisplatin combination) can improve the survival of these high risk patients of nasopharynx cancer who have elevated EBV-DNA after completion of their radiotherapy.

Eligibility criteria: Inclusion Criteria:

1. Have given written informed consent, prior to pre-study screening, with the understanding that consent may be withdrawn at any time without prejudice.
2. A histological diagnosis of nasopharyngeal cancer (NPC) must have been established at some time and the investigator must review and confirm the diagnosis prior to randomization.
3. Loco-regional advanced NPC UICC/AJCC Stages IIB, III, IVA or IVB.
4. No evidence of distant metastases in the staging work up at diagnosis.
5. Must have detectable plasma EBV-DNA (\> 0 copies/ml) at 6-8 weeks after completion of primary RT or chemo-RT
6. No clinical evidence of persistent loco-regional disease after primary treatment
7. Performance status of ECOG grade 0 or 1.
8. Patients must have adequate organ and marrow function as defined below:

   leukocytes \>3,000/L; absolute neutrophil count \>1,500/L; platelets \>100,000/L; total bilirubin \<1.5 X institutional upper limit of normal; AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal; Creatinine clearance \> 50 ml/min
9. At least 18 years of age, of either sex.
10. If female, must be either (i) post-menopausal or surgically sterilized, or (ii) use a hormonal contraceptive, intra-uterine device, diaphragm with spermicide for the duration of the study and must be neither pregnant nor breast-feeding.

Exclusion Criteria:

1. Hypercalcaemia: calcium \>= 2.7 mmol/L (10.8 mg/dL).
2. Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin).
3. More that 12 weeks after completion of primary radiotherapy.
4. Had received prior adjuvant chemotherapy.
5. Other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
6. Have serious active infection.
7. Patients with peripheral or ototoxicity with a grade of greater than 2.
8. Pregnant or lactating female subjects and subjects with reproductive potential not implementing adequate contraceptive measures.

Primary outcomes:
measure: Relapse free survival
timeFrame: 5 years
Secondary outcomes:
measure: Overall survival
timeFrame: 5 years
measure: Loco-regional control
timeFrame: 5 years
measure: Metastasis-free survival
timeFrame: 5 years
measure: Toxicity of adjuvant chemotherapy
timeFrame: 6 months
measure: Correlation of plasma EBV DNA and PET/CT scan with clinical course and outcome
timeFrame: 5 years
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital
city: Hong Kong
country: Hong Kong
facility: Department of Clinical Oncology, Prince of Wales Hospital
city: Hong Kong
country: Hong Kong
facility: Department of Clinical Oncology, Queen Elizabeth Hospital
city: Hong Kong
country: Hong Kong
facility: Department of Clinical Oncology, Queen Mary Hospital
city: Hong Kong
country: Hong Kong
facility: Department of Clinical Oncology, Tuen Mun Hospital
city: Hong Kong
country: Hong Kong
facility: Department of Oncology, Princess Margaret Hospital
Study officials:
affiliation: Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong
name: Anthony TC Chan, MD, FRCP
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong
name: Roger KC Ngan, FRCR
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chua ML, Chan AT. Gemcitabine: a game changer in nasopharyngeal carcinoma. Lancet. 2016 Oct 15;388(10054):1853-1854. doi: 10.1016/S0140-6736(16)31394-0. Epub 2016 Aug 23. No abstract available.